Stanford University |
James Dunn |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$772,098 |
University of California, Los Angeles |
Carla Koehler |
Tools and Technologies III |
A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs |
$1,283,900 |
University of California, San Diego |
Shyni Varghese |
Tools and Technologies III |
Technologies to improve in vivo function of transplanted stem cells |
$1,373,683 |
Scripps Research Institute |
Jeanne Loring |
Tools and Technologies III |
User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery |
$1,728,390 |
University of California, Los Angeles |
Leif Havton |
Tools and Technologies III |
Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases |
$1,308,711 |
University of California, Los Angeles |
James Dunn |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$1,044,423 |
University of California, Davis |
J. Leach |
Tools and Technologies III |
Multi-modal technology for non-destructive characterization of bioengineered tissues |
$1,574,151 |
University of California, Davis |
Laura Marcu |
Tools and Technologies III |
Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs |
$1,834,350 |
Gordon Research Conferences |
Leonard Zon |
Conference |
2015 Gordon Research Conference: Stem Cells & Cancer |
$20,000 |
City of Hope, Beckman Research Institute |
Fouad Kandeel |
Conference |
15th Annual Rachmiel Levine Diabetes and Obesity Symposium |
$20,000 |
Gladstone Institutes, J. David |
Steven Finkbeiner |
Conference |
THE 5TH ANNUAL CALIFORNIA ALS PAC10 AND RESEARCH NETWORK MEETING |
$9,529 |
University of California, San Diego |
Catriona Jamieson |
Alpha Stem Cell Clinics |
Alpha Stem Cell Clinic for the Development of Regenerative Therapies |
$8,679,137 |
University of California, Los Angeles |
John Adams |
Alpha Stem Cell Clinics |
UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium |
$8,680,000 |
City of Hope, Beckman Research Institute |
John Zaia |
Alpha Stem Cell Clinics |
The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,456,000 |
University of California, Davis |
Alice Tarantal |
Conference |
13th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$10,000 |
ViaCyte, Inc. |
Howard Foyt |
Accelerated Development Pathway I |
Clinical Development of a Cell Therapy for Diabetes |
$8,783,852 |
Sanford Consortium for Regenerative Medicine |
Edward Holmes |
Conference |
Stem Cell Meeting on the Mesa |
$40,000 |
University of California, San Francisco |
Susan Fisher |
Conference |
The Stem Cell Niche in Development and Disease |
$5,000 |
University of California, San Francisco |
Diana Laird |
Conference |
The 2014 Santa Cruz Developmental Biology Meeting |
$3,000 |
Lineage Cell Therapeutics, Inc. |
Francois Binette |
Strategic Partnership III Track A |
A Phase I/IIa Dose Escalation Safety Study of AST-OPC1 in Patients with Cervical Sensorimotor Complete Spinal Cord Injury |
$14,323,318 |
City of Hope, Beckman Research Institute |
John Zaia |
Strategic Partnership III Track A |
A Phase I, Open-Label Study To Assess The Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells (SB-728MR-HSPC) with Escalating Doses of Busulfan In HIV-1 (R5) Infected Sub... |
$5,583,438 |
University of California, Berkeley |
Xavier Darzacq |
Research Leadership |
Single Molecule Biophysics and Biology of Cellular Identity |
$4,175,924 |
Gladstone Institutes, J. David |
Todd McDevitt |
Research Leadership |
Engineering microscale tissue constructs from human pluripotent stem cells |
$5,849,100 |
University of California, Los Angeles |
John Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
University of California, Irvine |
Michelle Khine |
Conference |
UC Systemwide Bioengineering Symposium |
$7,525 |
Stanford University |
Fan Yang |
Conference |
2014 Materials Research Society (MRS) Spring Meeting:
Symposium Y: Biomaterials for Biomolecule Delivery and Understanding Cell-Niche Interactions |
$10,000 |
University of California, San Francisco |
Tippi MacKenzie |
Conference |
In Utero Hematopoietic Stem Cell Transplantation and Maternal-Fetal Tolerance |
$17,526 |
Biocom Institute |
Jennifer Landress |
Conference |
The 2014 BIO International Convention |
$50,000 |
University of California, San Diego |
Christian Metallo |
Basic Biology V |
Metabolic regulation of cardiac differentiation and maturation |
$1,124,834 |
Cedars-Sinai Medical Center |
Paul Noble |
Basic Biology V |
Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man |
$617,662 |
University of California, Los Angeles |
Samantha Butler |
Basic Biology V |
Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate |
$515,730 |
University of California, San Diego |
Cornelis Murre |
Basic Biology V |
Epigenetic mechanisms that enforce pluripotency in embryonic stem cells |
$1,160,997 |
University of California, San Diego |
Lawrence Goldstein |
Basic Biology V |
Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes |
$1,050,300 |
University of California, San Francisco |
Mark Anderson |
Basic Biology V |
Generation of a functional thymus to induce immune tolerance to stem cell derivatives |
$1,191,000 |
Palo Alto Veterans Institute for Research |
Thomas Rando |
Basic Biology V |
Molecular regulation of stem cell potency |
$966,510 |
Stanford University |
Helen Blau |
Basic Biology V |
Mass Cytometry to Delineate the Human Muscle Stem Cell Hierarchy and Dysfunction in Aging |
$1,175,357 |
University of California, Merced |
Kara McCloskey |
Basic Biology V |
Directed Differentiation of Specialized Endothelial Cells |
$475,686 |
Salk Institute for Biological Studies |
Ronald Evans |
Basic Biology V |
Metabolically-driven epigenetic changes in iPSC reprogramming |
$1,491,900 |
Gladstone Institutes, J. David |
Sheng Ding |
Basic Biology V |
A novel druggable mechanism to safeguard stem cell genome |
$1,294,495 |
University of California, Los Angeles |
Bennett Novitch |
Basic Biology V |
In vitro modeling of human motor neuron disease |
$1,147,114 |
University of California, San Diego |
Dianne McKay |
Basic Biology V |
Role of intracytoplasmic pattern recognition receptors in HSC engraftment |
$615,639 |
Stanford University |
Michael Snyder |
Genomics Centers of Excellence Awards (R) |
Center of Excellence for Stem Cell Genomics - Stanford |
$22,787,914 |
University of California, San Francisco |
Valerie Weaver |
Basic Biology V |
Biophysical Determinants of Early Embryonic Stem Cell Fate Specification |
$1,186,500 |
University of California, Irvine |
Peter Donovan |
Basic Biology V |
Non-invasive live imaging of stem cell signature metabolic states |
$516,366 |
Salk Institute for Biological Studies |
Joseph Ecker |
Genomics Centers of Excellence Awards (R) |
Center of Excellence for Stem Cell Genomics - Salk |
$13,201,635 |
University of California, San Diego |
David Cheresh |
Basic Biology V |
CD61-driven stemness program in epithelial cancer |
$1,161,000 |
University of California, Santa Cruz |
Joshua Stuart |
Genomics Centers of Excellence Awards (R) |
Center of Excellence for Stem Cell Genomics - UCSC |
$3,999,083 |
University of California, Berkeley |
Andrew Dillin |
Basic Biology V |
A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health |
$1,034,100 |
University of Southern California |
Denis Evseenko |
Basic Biology V |
Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes |
$735,138 |
University of California, San Diego |
Miles Wilkinson |
Basic Biology V |
New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors |
$552,811 |
University of California, San Diego |
Maike Sander |
Basic Biology V |
Defining links between chromatin state and developmental competence |
$1,050,300 |
University of California, San Diego |
Wei Wang |
Basic Biology V |
Systems-level discovery of the regulatory mechanisms directing differentiation of hESC |
$1,161,000 |
Stanford University |
Marius Wernig |
Basic Biology V |
Mechanisms of human induced neuronal cell reprogramming |
$1,178,370 |
Stanford University |
Xinnan Wang |
Basic Biology V |
Misregulated Mitophagy in Parkinsonian Neurodegeneration |
$1,174,943 |
Stanford University |
Gary Steinberg |
Basic Biology V |
Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery |
$1,178,370 |
California Institute of Technology |
David Tirrell |
Basic Biology V |
Engineered matrices for control of lineage commitment in human pancreatic stem cells |
$526,896 |
University of California, Los Angeles |
Lili Yang |
Basic Biology V |
Differentiation of Human Hematopoietic Stem Cells into iNKT Cells |
$614,400 |
University of California, Irvine |
Lisa Flanagan |
Basic Biology V |
Molecular basis of plasma membrane characteristics reflecting stem cell fate potential |
$994,108 |
University of California, Los Angeles |
Denis Evseenko |
Basic Biology V |
Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes |
$411,330 |
University of California, San Francisco |
Jason Rock |
Conference |
Tri-Institutional Stem Cell Retreat |
$3,500 |
Stanford University |
Thomas Rando |
Conference |
Third Annual Symposium on Regenerative Rehabilitation |
$20,000 |
Human Organ Project |
Anita Caufield |
Conference |
Regenerative Medicine Foundation 2014 Conference |
$50,000 |
Stanford University |
Joseph Wu |
Conference |
Cardiovascular Regenerative Medicine Symposium |
$9,000 |
University of California, San Diego |
Thomas Kipps |
Disease Team Therapy Development III |
Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) |
$4,179,598 |
Stanford University |
Irving Weissman |
Disease Team Therapy Development III |
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors |
$6,505,568 |
University of California, Los Angeles |
Donald Kohn |
Disease Team Therapy Development III |
Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease |
$13,145,465 |
University of California, Davis |
Peter Belafsky |
Disease Team Therapy Development III |
Tissue Engineered Recellularized Laryngotracheal Implants |
$3,181,162 |
University of Southern California |
Mark Humayun |
Disease Team Therapy Development III |
Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration |
$16,339,827 |
University of California, Los Angeles |
Dennis Slamon |
Disease Team Therapy Development III |
A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors |
$5,683,693 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Conference |
Keystone Symposia, "Stem Cells and Reprogramming" |
$50,000 |
University of California, Davis |
Mark Yarborough |
Conference |
Stem Cell Research for Neurological Disorders: A Case Study in Ethical and Policy Issues in ALS Research |
$1,020 |
University of California, San Francisco |
Jeffrey Rosenfeld |
Conference |
California ALS Research Summit 2014 |
$8,563 |
Alliance Forum Foundation |
George Hara |
Conference |
2013 World Alliance Forum in San Francisco |
$3,500 |
University of California, Los Angeles |
Dana Jones |
Conference |
7th CA/HSCI Junior PI Conference: Stem Cells 2.0 |
$2,500 |
Sanford Consortium for Regenerative Medicine |
Edward Holmes |
Conference |
The Sanford Consortium for Regenerative Medicine's Scientific Symposium and the Regen Med Partnering Forum at Stem Cell Meeting on the Mesa VIII |
$35,000 |
University of California, San Francisco |
Regis Kelly |
Conference |
The Science of Staying Younger Longer |
$6,500 |
University of California, Davis |
Alice Tarantal |
Conference |
12th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$8,000 |
Scripps Research Institute |
Jeanne Loring |
Conference |
World Stem Cell Summit |
$30,000 |
Numerate, Inc. |
John Griffin |
Early Translational IV |
Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin |
$520,015 |
Sanford Burnham Prebys Medical Discovery Institute |
Stuart Lipton |
Early Translational IV |
Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke |
$1,020,815 |
Stanford University |
Michele Calos |
Early Translational IV |
Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B |
$1,876,253 |
University of California, Los Angeles |
Robert Reiter |
Early Translational IV |
Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells |
$4,075,668 |
The Scintillon Institute |
Stuart Lipton |
Early Translational IV |
Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke |
$1,103,185 |
University of California, Los Angeles |
Zack Jerome |
Early Translational IV |
Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection |
$4,925,166 |
University of California, Irvine |
Magdalene Seiler |
Early Translational IV |
Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) |
$3,998,948 |
University of California, Los Angeles |
Donald Kohn |
Early Translational IV |
Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells |
$1,651,884 |
Salk Institute for Biological Studies |
Inder Verma |
Early Translational IV |
Development of a cell and gene based therapy for hemophilia |
$2,298,634 |
Human BioMolecular Research Institute |
John Cashman |
Early Translational IV |
Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model |
$6,361,369 |
University of California, Los Angeles |
Gerald Lipshutz |
Early Translational IV |
Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders |
$1,801,629 |
Cedars-Sinai Medical Center |
Dan Gazit |
Early Translational IV |
Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing |
$5,121,514 |
University of California, San Diego |
Alysson Muotri |
Early Translational IV |
A drug-screening platform for autism spectrum disorders using human astrocytes |
$1,656,456 |
Gladstone Institutes, J. David |
Steven Finkbeiner |
Early Translational IV |
Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases |
$2,049,053 |
Stanford University |
Julien Sage |
Conference |
3rd International RB conference |
$10,000 |
University of California, San Francisco |
Peter Stock |
Conference |
IPITA 2013 - 14th World Congress of the International Pancreas and Islet transplant Association |
$10,000 |
OCTANe Foundation for Innovation |
Matthew Jenusaitis |
Conference |
Orange County Summit on Regenerative Medicine (OCSRM) |
$2,500 |
University of California, San Diego |
Joan Heller Brown |
Conference |
International Society for Heart Research (ISHR) XX1 World Congress |
$10,000 |
Sangamo BioSciences, Inc. |
Fyodor Urnov |
Strategic Partnership II |
A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells |
$2,760,540 |
Cedars-Sinai Medical Center |
Barry Stripp |
Research Leadership |
Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
Stanford University |
Hiromitsu Nakauchi |
Research Leadership |
Generation of functional cells and organs from iPSCs |
$5,426,135 |
University of California, San Diego |
Eric Ahrens |
Research Leadership |
Molecular Imaging for Stem Cell Science and Clinical Application |
$5,680,474 |